Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
20 oct. 2021 08h30 HE
|
Radius Health Inc.; Menarini Group
Study met both primary endpoints in patients with ER+/HER2- advanced or mBCElacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the...
Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
18 oct. 2021 08h30 HE
|
Radius Health Inc.
ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value < 0.0001)Study also met secondary endpoints relating to bone mineral density changes in...
TYMLOS Label and Business Update
22 sept. 2021 08h00 HE
|
Radius Health Inc.
TYMLOS® label: significant update to the Mechanism of Action (MOA) sectionLabel change aligns with strategic focus on postmenopausal women at high risk of fractureDanielle Holtschlag joins as Head of...
Radius Health, Inc.: Second Quarter and Year-to-Date Results
05 août 2021 07h00 HE
|
Radius Health Inc.
Repositioned the Company to create meaningful P+L operating leverageDramatic improvement in Adj. EBITDA performance: ($6) million in Q2, 2021 vs. ($29) million in Q2, 2020FY 2021 guidance: reiterate...
Radius Health Business Update
27 juil. 2021 08h00 HE
|
Radius Health Inc.
Added 5,000+ new TYMLOS patients in Q2, 2021, up 40+% vs. Q2, 2020 and 3% vs. Q1, 2021ATOM and wearABLe abaloparatide Phase 3 trial readouts remain on track for 2H, 2021EU abaloparatide regulatory...
CORRECTION: Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
23 juil. 2021 11h12 HE
|
Radius Health Inc.
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studiesBased on results, a...
Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
22 juil. 2021 09h00 HE
|
Radius Health Inc.
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studiesBased on results, a...
Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021
20 juil. 2021 17h11 HE
|
Radius Health Inc.
BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021. The Company will...
Radius Health Business Update
02 juin 2021 08h15 HE
|
Radius Health Inc.
TYMLOS® new patient adds in April: modest growth vs. previous 4-month trailing averages~67% of new patients in April were initiated by a fracture focused bone health accountMeaningful FDA guidance on...
Radius Health, Inc.: First Quarter 2021 Results
07 mai 2021 06h30 HE
|
Radius Health Inc.
Total net revenue: $56 million vs. $48 million in Q1, 2020, +17% year-over-yearTYMLOS® U.S. product net revenue: $45 million vs. $48 million in Q1, 2020, -6% year-over-yearSignificant operating...